In-hospital stroke treated with intravenous tissue plasminogen activator

Stroke. 2008 Sep;39(9):2614-6. doi: 10.1161/STROKEAHA.107.512848. Epub 2008 Jul 17.

Abstract

Background and purpose: In-hospital strokes (IHSs) are potential candidates for thrombolysis. We analyzed the treatment procedures, safety, and efficacy of intravenous tissue plasminogen activator (IV-tPA) in IHSs compared with out-of-hospital strokes (OHSs).

Methods: This study was based on a multicenter prospective registry of patients treated with IV-tPA divided into IHSs and OHSs. We recorded intrahospital delays and stroke outcomes.

Results: Among 367 patients treated with IV-tPA, 30 were IHSs. Baseline characteristics were similar except for a greater proportion of diabetes (36.7% vs 17.5%, P=0.01), cardiac failure (16.7% vs 5.3%, P=0.014), and atrial fibrillation (33.3% vs 17.5%, P=0.034) in IHSs than OHSs. In-hospital delays were significantly longer in IHSs for door-to-computed tomography time (39.5+/-18.7 vs 22.6+/-19.7 minutes, P<0.0001) and computed tomography-to-treatment time (92.0+/-26.1 vs 65.4+/-25.8 minutes, P<0.0001). No differences were observed in safety or efficacy.

Conclusions: In-hospital procedures for thrombolysis proceed more slowly in IHSs than in OHSs. Thrombolysis is safe and efficient in IHS.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / epidemiology
  • Diabetes Mellitus / epidemiology
  • Early Diagnosis
  • Emergency Medical Services / statistics & numerical data
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Heart Failure / epidemiology
  • Hospitalization / statistics & numerical data*
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Prospective Studies
  • Quality of Health Care / trends
  • Registries
  • Stroke / drug therapy*
  • Stroke / nursing
  • Thrombolytic Therapy / methods
  • Thrombolytic Therapy / statistics & numerical data*
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator